

Financial news for NYMX dated on 2020-04-03: Nymox Pharmaceutical Corp Files For Mixed Shelf Offering Of Up To \$12M

Financial news for NYMX dated on 2020-02-24: Nymox Pharma Highlights New Peer Review Publication Of Its Prostate Cancer Candidate Fexapotide In World Journal Of Urology

Financial news for NYMX dated on 2020-02-07: 100 Biggest Movers From Yesterday

Financial news for NYMX dated on 2020-02-06: 74 Stocks Moving In Thursday's Mid-Day Session

Financial news for NYMX dated on 2020-01-31: Stocks That Hit 52-Week Highs On Friday

Financial news for NYMX dated on 2020-01-31: The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO

Financial news for NYMX dated on 2020-01-31: 70 Biggest Movers From Yesterday

Financial news for NYMX dated on 2020-01-30: Stocks That Hit 52-Week Highs On Thursday

Financial news for NYMX dated on 2020-01-28: Nymox Pharma Offers Corporate, Milestone Update

Financial news for NYMX dated on 2020-01-07: The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering

Financial news for NYMX dated on 2020-01-06: Nymox Highlights New Peer Review Article On Fexapotide Pharmacologic Ablation Experimental Studies Published In Research And Reports In Urology

Financial news for NYMX dated on 2020-01-06: 24 Stocks Moving in Monday's Pre-Market Session

Financial news for NYMX dated on 2020-01-06: 53 Biggest Movers From Friday

Financial news for NYMX dated on 2020-01-03: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for NYMX dated on 2019-12-27: 60 Biggest Movers From Yesterday

Financial news for NYMX dated on 2019-10-21: Nymox Reports Received Several New Added US, European Patents

Financial news for NYMX dated on 2019-10-16: Nymox Pharmaceutical Granted European Patent Number Ep3432907 Titled "Neural Thread Peptide For Preventing Or Reducing The Progression Of Prostate Cancer

Financial news for NYMX dated on 2019-06-25: Nymox Releases End Of Q2 Investor Presentation On Website

Financial news for NYMX dated on 2019-06-06: Nymox Director Robinson Buys 11,000 @ Avg Price: \$1.55

Financial news for NYMX dated on 2019-05-28: Nymox Pharmaceutical Director James Robinson Buys 7,500 @ Avg Price: \$1.55

Financial news for NYMX dated on 2019-04-16: Nymox Pharmaceutical Has Held Its Pre-New Drug Application Chemistry Manufacturing And Controls Meeting With FDA Regarding Its Lead Product Candidate Fexapotide Trifluoromethane, A Novel Prostate Injectable Developed For The Treatment Of Enlarged Prostate

Financial news for NYMX dated on 2019-01-22: 50 Stocks Moving In Tuesday's Mid-Day Session

Financial news for NYMX dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for NYMX dated on 2018-11-21: Nymox Pharmaceutical Corp Director Robinson Buys 6,000 @ Avg Price: \$1.78

Financial news for NYMX dated on 2018-10-26: Nymox Pharmaceutical Director Robinson Buys 10,000 @ Avg Price: \$1.62

Financial news for NYMX dated on 2018-10-25: Nymox Pharmaceutical Director Robinson Buys 8,000 @ Avg Price: \$1.67

Financial news for NYMX dated on 2018-10-18: Nymox Pharmaceutical Option Alert: Jan

18 \$3 Puts at the Bid: 749 @ \$1.601 vs 3480 OI; Earnings 11/5 After Close [est]
Ref=\$1.72

Financial news for NYMX dated on 2018-10-15: 44 Biggest Movers From Yesterday

Financial news for NYMX dated on 2018-10-12: The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

Financial news for NYMX dated on 2018-10-11: Nymox Pharmaceutical Corporation Says Preparatory Work For Regulatory Filings 'On Track'

Financial news for NYMX dated on 2018-10-11: Stocks Which Set New 52-Week Low Yesterday, October 10th

Financial news for NYMX dated on 2018-10-11: The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares

Financial news for NYMX dated on 2018-10-09: Nymox Reports 78 Month Results From Biopsy And Surgery Confirmed Prospective Randomized NX03-0040 Prostate Cancer Study Of Fexapotide Triflutate: Gleason Grade Progression Reduced By 81% Overall

Financial news for NYMX dated on 2018-10-04: Stocks Which Set New 52-Week Low Yesterday, October 3rd

Financial news for NYMX dated on 2018-10-03: Stocks Which Set New 52-Week Low Yesterday, October 2nd

Financial news for NYMX dated on 2018-10-03: Nymox Reports 'no identifiable risks or serious side effects or adverse events identified associated or linked with' Fexapotide Treatments For Prostate Cancer, Benign Prostatic Hyperplasia

Financial news for NYMX dated on 2018-10-02: Stocks Which Set New 52-Week Low Yesterday, October 1st

Financial news for NYMX dated on 2018-08-16: Stocks Which Set New 52-Week Low Yesterday, August 15th

Financial news for NYMX dated on 2018-08-16: The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait

Financial news for NYMX dated on 2018-08-16: 60 Biggest Movers From Yesterday

Financial news for NYMX dated on 2018-08-15: 55 Stocks Moving In Wednesday's Mid-Day Session

Financial news for NYMX dated on 2018-08-13: Nymox Pharmaceutical Q2 EPS \$(0.04) vs \$(0.05) In Same Qtr. Last Year, Sales \$88.411K vs \$9.432K YoY

Financial news for NYMX dated on 2018-07-03: 44 Biggest Movers From Yesterday

Financial news for NYMX dated on 2018-07-02: '\$NYMX PR headline: "NYMOX Announces Expanded Marketing Plans" But then you read down to 4th paragraph where it says the EMA submission has been withdrawn. Oh...' - STAT News' Adam F Tweets

Financial news for NYMX dated on 2018-07-02: Nymox Pharmaceutical Announces Expanded European Marketing Plans For Fexapotide Triflutate

Financial news for NYMX dated on 2018-06-26: 44 Biggest Movers From Yesterday

Financial news for NYMX dated on 2018-06-25: 36 Stocks Moving In Monday's Mid-Day Session

Financial news for NYMX dated on 2018-06-25: 50 Biggest Movers From Friday

Financial news for NYMX dated on 2018-05-07: Nymox Pharma Reports Initiation Of Process To Relocate Co. HQ From Nassau, Bahamas To Zug, Switzerland

Financial news for NYMX dated on 2018-04-12: Nymox Announces \$16.25M Equity Financing With Qualified Long-Term Investors; Lead Investor Will Receive 2.5M Warrants At \$8/Share For Their \$12M Investment

Financial news for NYMX dated on 2018-03-28: 38 Biggest Movers From Yesterday

Financial news for NYMX dated on 2018-03-16: Nymox Pharm Robinson James George (Director) Buys 8,000 @ Avg Price: \$3.58 (Form4)

Financial news for NYMX dated on 2018-03-12: Nymox Pharmaceutical Corp: Robinson James George (Director) Buys 8,000 @ Avg Price: \$3.48 (Form4)

Financial news for NYMX dated on 2018-02-12: Nymox Pharma Director Robinson Buys 7,000 @ Avg Price: \$3.18 -Form4

Financial news for NYMX dated on 2018-02-05: Nymox Announces It Will Submit A NDA For Fexapotide for BPH Later This Year

Financial news for NYMX dated on 2018-01-30: Nymox Pharma Reports Results Of Phase 3 Studies Of Fexapotide Triflutate Over '09-'16 Now Published In WJU

Financial news for NYMX dated on 2018-01-22: Nymox Pharmaceutical Director James George Robinson Buys 3,000 @ Avg Price: \$3.14 -Form4

Financial news for NYMX dated on 2018-01-22: UPDATE: Nymox Pharma Says '81.3% Reduction in Incidence of Primary Pattern Gleason Grade Increase Compared to Control Group'

Financial news for NYMX dated on 2018-01-22: Nymox Pharma Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study Of Fexapotide Triflutate In 146 US Men: 'Single-Treatment Leads to Long-Term 80% Reduction in Surgery and Radiotherapy...'

Financial news for NYMX dated on 2018-01-04: Nymox Option Alert: Jan, 2019 \$3 Puts Sweep (6) at the Ask: 1000 @ \$0.951 vs 1167 OI; Ref=\$3.4164

Financial news for NYMX dated on 2017-11-16: NYMOX Shares Slightly Volatile Here As Co. Issues Release Highlighting Symposium Held On Fexapotid Trifultate Studies At AUA

Financial news for NYMX dated on 2017-11-07: Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana

Financial news for NYMX dated on 2017-11-06: Nymox Pharma 6-K Shows EPS \$(0.09) vs \$(0.07) In Same Qtr. Last Year, Sales \$30.878M vs \$51.98M YoY

Financial news for NYMX dated on 2017-11-01: Nymox Option Alert: Dec 15 \$4 Puts Sweep (2) at the Ask: 500 @ \$0.7 vs 0 OI; Ref=\$3.52

Financial news for NYMX dated on 2017-10-26: Nymox Shares Spike To High Of \$3.85 As Co. Announces Two Data Presentations for Company's BPH Drug at New York American Urological Association Meeting November 6

Financial news for NYMX dated on 2017-10-13: Nymox Shares Spiking Higher, Up 2.96% Following PR Highlighting Panel Discussion With Abstract On Fexapotide At American Urological Association Northeast Sectional Annual Meeting in Savannah

Financial news for NYMX dated on 2017-09-14: Nymox Application Validated in EU

Financial news for NYMX dated on 2017-09-14: Nymox Pharma Announces Its MAA Application With European Member States Has Been Validated For Fexapotide Triflutate

Financial news for NYMX dated on 2017-08-09: Nymox Reports Private Placements of \$3 Million

Financial news for NYMX dated on 2017-06-30: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for NYMX dated on 2017-06-21: Nymox Pharmaceutical Director James George Robinson Buys 15,000 @ Avg Price: \$3.77 -Form4

Financial news for NYMX dated on 2017-05-31: Form 4 Filing from Nymx Pharma by George James Robinson Shows Purchase of 54,500 Shares Over Numerous Transactions

Financial news for NYMX dated on 2017-05-31: Nymox Pharmaceutical Reports Statistically Significant Clinical Trial Results Showing Fexapotide Triflutate Improvements In First-Line Patients

Financial news for NYMX dated on 2017-05-16: Nymox Pharma Q1 EPS \$(0.06) vs \$(0.08) YoY, Sales \$78.39K vs \$41.50K YoY

Financial news for NYMX dated on 2017-05-10: Nymox Shares Spike Higher, Turn Positive, Now Up 1.7%; BZ NOTE: News of Filing for Approval Was Disclosed Last Week, Press Release Wednesday Was Strictly to Highlight Conference Call

Financial news for NYMX dated on 2017-05-10: Nymox Pharma Shares Spike \$0.30 as Co. Issues Press Release Highlighting Conference Call on May 10 at 4:30 p.m. EDT to Discuss Filing for Approval of Prostate Drug in Europe

Financial news for NYMX dated on 2017-05-03: NYMOX Issues Release Highlighting Filing for Marketing Approval for Fexapotide Triflutate in Europe

Financial news for NYMX dated on 2017-04-26: Benzinga's Option Alert Recap From April 26

Financial news for NYMX dated on 2017-04-26: Option Alert: Nymox May 5.0 Calls: 710 @ ASK \$0.50: 730 traded vs 3662 OI: Earnings 5/16 Unspecified [est] \$4.93 Ref

Financial news for NYMX dated on 2017-04-03: Benzinga's Option Alert Recap From April 3

Financial news for NYMX dated on 2017-04-03: Option Alert: Nymox Apr 4.0 Calls: 750 @ ASK \$0.20: 750 traded vs 563 OI: Earnings today After Close (est) \$3.67 Ref

Financial news for NYMX dated on 2017-04-03: Nymox Pops to High of \$3.84 on Volume

Financial news for NYMX dated on 2017-03-30: Watch These 5 Huge Put Purchases In Thursday Trade

Financial news for NYMX dated on 2017-03-29: Option Alert: Nymox Apr 3.0 Puts: 500 @ ASK \$0.15: 503 traded vs 1051 OI: Earnings tmrrw After Close (est) \$3.72 Ref

Financial news for NYMX dated on 2017-03-29: Nymox Pharma Says Sees Submitting Initial Filing Seeking Approval for Fexapotide Triflutate in Next Few Weeks

Financial news for NYMX dated on 2017-01-09: Option Alert: Nymox Feb 2.5 Puts: 500 @ ASK \$0.50: 500 traded vs 2559 OI: Earnings 3/28 After Close (est) \$2.86 Ref

Financial news for NYMX dated on 2016-11-29: Nymox Pharma Shares to Resume Trade at 9:50:43 a.m. EDT

Financial news for NYMX dated on 2016-11-29: UPDATE: Nymox Says Results Confirm That Patients Who Received Fexapotide as Initial Treatment for PBH Had Superior Efficacy Results as Early as 10 Days

Financial news for NYMX dated on 2016-11-29: Nymox Pharma Reports Added Positive Results from Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response, First-Line Efficacy

Financial news for NYMX dated on 2016-11-29: Nymox Pharmaceutical Halted On Circuit Breaker

Financial news for NYMX dated on 2016-11-15: 6-K from Nymox Pharma Shows Q3 EPS \$(0.07) vs \$(0.26) in Same Qtr. Last Year, Sales \$51.98M vs \$46.852M YoY

Financial news for NYMX dated on 2016-11-07: 10 Stocks That Plummeted The Past Three Days On Increasing Volume

Financial news for NYMX dated on 2016-10-24: 25 Stocks Which Rallied Four Days, Then Sold Off On Friday

Financial news for NYMX dated on 2016-10-12: 5 Stocks Which Rallied Three Days On Increasing Volume

Financial news for NYMX dated on 2016-10-11: Mid-Afternoon Market Update: Dow Drops 250 Points; Biostar Pharmaceuticals Shares Spike Higher

Financial news for NYMX dated on 2016-10-11: 8 Biggest Mid-Day Gainers For Tuesday

Financial news for NYMX dated on 2016-10-11: Mid-Day Market Update: Rent-A-Center Drops On Disappointing Q3 Outlook; Nymox Shares Surge

Financial news for NYMX dated on 2016-10-11: Nymox Shares Up 32% At \$4.36

Financial news for NYMX dated on 2016-10-11: Nymox Halted on CB

Financial news for NYMX dated on 2016-10-11: Nymox Announces Successful New Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results: Lasting Symptomatic Improvement Up To 6 Years After Single Repeated Treatment [

Financial news for NYMX dated on 2016-10-11: Nymox Reports Successful New Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results: Lasting Symptomatic Improvement Up To 6 Years After Single Repeated Treatment

Financial news for NYMX dated on 2016-09-13: 10 Biggest Mid-Day Gainers For Tuesday

Financial news for NYMX dated on 2016-08-29: Adam Feuerstein @adamfeuerstein Tweet: \$NYMX issues new PR this morning which just repeats the same misleading, erroneous talking points about failed fexapotide clinical trials. 10:34am * 29 Aug 2016

Financial news for NYMX dated on 2016-08-29: Nymox Highlights Phase 3 LT U.S. Results For Prostate Enlargement, BZ NOTE: The Street's Adam Feuerstein Has Been Notably Bearish On The Stock Recently

Financial news for NYMX dated on 2016-08-29: Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show Dramatic Decrease in Prostate Cancer, Major Reduction in Need For BPH Prostate Surgery

Financial news for NYMX dated on 2016-08-26: MoxReports @MoxReports Tweet: \$nymx. Yes...still short. It's a zero. But very expensive borrow.

Financial news for NYMX dated on 2016-08-26: Adam Feuerstein @adamfeuerstein Tweet: Jabbing A Needle in the Overinflated \$NYMX Prostate Drug Hype
thestreet.com/story/13686959...

Financial news for NYMX dated on 2016-08-26: 12 Biggest Mid-Day Losers For Friday

Financial news for NYMX dated on 2016-08-25: 18 Biggest Mid-Day Gainers For Thursday

Financial news for NYMX dated on 2016-08-25: Mid-Day Market Update: Dollar General Falls Following Weak Results; AEP Industries Shares Spike Higher

Financial news for NYMX dated on 2016-08-25: Mid-Morning Market Update: Markets Edge Lower; Tiffany Profit Beats Estimates

Financial news for NYMX dated on 2016-08-25: Adam Feuerstein @adamfeuerstein Tweet:\$NYMX -- For those new to the stock, a couple of older stories to warn you away. thestreet.com/story/11003461... thestreet.com/story/12775982...

Financial news for NYMX dated on 2016-08-25: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for NYMX dated on 2016-08-25: Adam Feuerstein @adamfeuerstein Tweet: @RobertDurant7 There's really nothing to discuss w/r/t \$NYMX. The "drug" is total zero w/ years of delays and failures behind it.

Financial news for NYMX dated on 2016-08-24: After-Hours Gainers Aug. 24, 2016: GES Up 15%, TLYS 10.2%, BLDP 10%, WDAY 9.9%, NYMX 7.8%

Financial news for NYMX dated on 2016-08-24: Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery By 82-95%

Financial news for NYMX dated on 2016-08-17: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for NYMX dated on 2016-08-17: Nymox Pharma Reports Private Placements of \$2.24M

Financial news for NYMX dated on 2016-08-11: 18 Biggest Mid-Day Gainers For Thursday

Financial news for NYMX dated on 2016-08-11: MoxReports @MoxReports Tweet: \$nymx still short. thesis is unchanged. pr is nonsense, as usual.

Financial news for NYMX dated on 2016-08-11: UPDATE: Nymox Reports Major Progress in Evidence for Safety, Efficacy of Fexapotide for BPH, Low-Grade Prostate Cancer

Financial news for NYMX dated on 2016-08-11: Nymox Announces Prostate Drug Progress

Financial news for NYMX dated on 2016-08-10: Nymox Pharmaceutical Halted on CB at Low of \$1.83

Financial news for NYMX dated on 2016-08-10: Nymox off Low @\$2.89; May be Attributed to Negative Mox Report

Financial news for NYMX dated on 2016-06-22: Mid-Afternoon Market Update: Dow Turns Lower; Crude Oil Slides Over 2%

Financial news for NYMX dated on 2016-06-22: 10 Biggest Mid-Day Gainers For Wednesday

Financial news for NYMX dated on 2016-06-22: Shares of Nymox Pharma to Resume Trade at 10 a.m. EDT

Financial news for NYMX dated on 2016-06-22: Nymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study of 995 U.S. Middle-Aged and Elderly Men Without Cancer

Financial news for NYMX dated on 2016-06-22: Nymox Pharma Shares Halted News Pending

Financial news for NYMX dated on 2016-02-09: Nymox Says Study Successfully Met Its

Pre-Determined Endpoints

Financial news for NYMX dated on 2016-02-04: Nymox Reports Private Equity Placement Of \$2.1M At \$2/Share, Investments Made By Long-Time Shareholders

Financial news for NYMX dated on 2016-02-04: Nymox Reports Added \$2.1M in Equity Financing

Financial news for NYMX dated on 2016-01-13: Director Robinson Buys 20,000 Shares of Nymox Pharmaceutical \$2.44/Share -Form 4

Financial news for NYMX dated on 2015-12-31: Nymox Pharma Reports Filing of Current Financial Statements

Financial news for NYMX dated on 2015-12-24: DJ Dir Robinson Buys 29,854 Shares of Nymox Pharmaceutical @\$3.54/Share -Form 4

Financial news for NYMX dated on 2015-12-10: Mid-Afternoon Market Update: American Superconductor Gains On Strong Q3 Outlook; First Solar Shares Drop

Financial news for NYMX dated on 2015-10-29: UPDATE: Nymox Results Show Primary Endpoint Of Cross-Over Study Of Fexapotide Reached Statistical Significance

Financial news for NYMX dated on 2015-10-29: Nymox Reports Results of Prospective Cross-Over Study of Fexapotide Treatment for Prostate Cancer

Financial news for NYMX dated on 2015-10-08: Nymox Announces Prostate Cancer Clinical Trial Will Complete Prospective 18 Month Post-Treatment Assessments

Financial news for NYMX dated on 2015-09-08: Nymox Pharmaceutical Director Robinson Buys 100,000 Shares @\$2.25/Share -Form 4

Financial news for NYMX dated on 2015-08-12: UPDATE: Pedone Looking for Shares of Nymox to Close Over \$3.31; If Shares Don't Close Over This Level, Warns Price 'subject to fail the break out and will get faded'

Financial news for NYMX dated on 2015-08-12: Zero Sum Trading's Roberto Pedone Highlighting Technical Levels in Shares of Nymox Pharma: Price 'failed at a clear resistance level of \$3.25 after hitting an intraday high of \$3.31'

Financial news for NYMX dated on 2015-07-27: Market Update: Monday's Mid-Day Movers, China's Stock Market Crash And More

Financial news for NYMX dated on 2015-07-27: Sophiris Mentioned as Play on Nymox

Financial news for NYMX dated on 2015-07-27: Nymox Pharmaceutical Halted on Circuit Breaker +127%

Financial news for NYMX dated on 2015-07-27: Shares of Nymox Pharma Now Up Nearly 55%

Financial news for NYMX dated on 2015-07-27: Nymox Shares Rise 87% as Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint

Financial news for NYMX dated on 2015-07-27: Shares of Nymox Open for Trade Up 37.5%

Financial news for NYMX dated on 2015-07-27: Shares of Nymox Halted News Pending

Financial news for NYMX dated on 2015-07-14: F-3 Filing Shows Nymox Pharmaceuticals To Offer 12M Shares By Selling Shareholders

Financial news for NYMX dated on 2015-06-16: Nymox Pharma Reports \$850K Financing at Prices of \$1.25-\$1.66

Financial news for NYMX dated on 2015-05-13: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROI

Financial news for NYMX dated on 2015-05-06: Top Performing Industries For May 6, 2015

Financial news for NYMX dated on 2015-04-20: UPDATE: Nymox Shares Rise 56% on Positive Prostate Cancer Trial Results

Financial news for NYMX dated on 2015-04-20: Nymox Reports New Prostate Cancer Clinical Trial Results

Financial news for NYMX dated on 2015-04-06: These 5 Stocks Have More Than Doubled In 2015

Financial news for NYMX dated on 2015-04-01: Shares of Nymox Pharma to Resume Trade

at 10:30 a.m. EDT

Financial news for NYMX dated on 2015-04-01: Nymox Announces Phase 3 BPH Studies

Financial news for NYMX dated on 2015-04-01: shares of Nymox Pharma Halted News Pending

Financial news for NYMX dated on 2015-01-22: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROI

Financial news for NYMX dated on 2014-12-18: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROI

Financial news for NYMX dated on 2014-11-14: Nymox Pharmaceutical Corporation Reports Q3 EPS of \$(0.02), Up 75% YOY; Revenue of \$81.13K

Financial news for NYMX dated on 2014-11-03: Stocks Hitting 52-Week Lows

Financial news for NYMX dated on 2014-11-03: Morning Market Losers

Financial news for NYMX dated on 2014-11-03: Nymox Shares Fall 79% Premarket on Failed NX-1207 Trial

Financial news for NYMX dated on 2014-11-02: Nymox Reports NX-1207 BPH Pivotal Phase 3 U.S. Studies Fail to Meet Primary Efficacy Endpoints

Financial news for NYMX dated on 2014-09-10: Nymox Announces Positive Prostate Cancer 8-Month Clinical Trial Results, Statistical Significance Reduced Compared to Controls

Financial news for NYMX dated on 2014-08-11: Nymox Pharmaceutical Corporation Reports Q2 EPS of \$(0.02), Up 75% YOY; Revenue of \$97.88K, Down 88% YOY

Financial news for NYMX dated on 2014-07-22: Nymox Announces Positive Efficacy in Phase III NX-1207

Financial news for NYMX dated on 2014-07-15: Nymox Announces Completion of Enrollment For Second BPH Study

Financial news for NYMX dated on 2014-07-14: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROI

Financial news for NYMX dated on 2014-06-17: Nymox Pharma Offers Update on Nerve Sparing, Sexual Function Related to Men Treated with NX-1207

Financial news for NYMX dated on 2014-06-11: Nymox Offers Positive New Safety Study Data for Phase 3 BPH Drug

Financial news for NYMX dated on 2014-05-21: Nymox Pharma Reports Targeted Treatment With NX-1207 at Either Dose Had No Significant Effect on Reported Sexual Function Score Post-Treatment

Financial news for NYMX dated on 2014-05-15: Nymox Pharmaceutical Corporation Reports Q1 EPS of \$(0.07), Up 13% YOY; Revenue of \$78.0K vs \$890.0K Est

Financial news for NYMX dated on 2014-05-13: Nymox Reports Positive Results on NX-1207: Does Not Affect Testosterone Levels

Financial news for NYMX dated on 2014-05-08: Nymox Announces Completion of Second Phase 3 NX-1207 Trial for BPH

Financial news for NYMX dated on 2014-05-06: Nymox Reports New Prostate Cancer Clinical Trial Results

Financial news for NYMX dated on 2014-05-05: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROE

Financial news for NYMX dated on 2014-04-30: Mid-Day Market Update: Twitter Drops On Earnings; Pepco Shares Gain

Financial news for NYMX dated on 2014-04-30: Shares of Nymox Sharply Lower by 5.5% After Reporting Top-Line Results from Phase 2 Study of NX03-0040

Financial news for NYMX dated on 2014-04-30: UPDATE: Nymox Pharmaceutical Shares Resume Trading Down 7% Following Release of Prostate Cancer Study Showing Mixed Results

Financial news for NYMX dated on 2014-04-30: Shares of Nymox Pharma Halted News Pending

Financial news for NYMX dated on 2013-11-11: Nymox Reports Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH

Financial news for NYMX dated on 2013-08-22: Nymox Pharma Issues Results on NX02-0018 Phase Trial, Initial Blush Looks Positive

Financial news for NYMX dated on 2013-07-16: Afternoon Market Gainers

Financial news for NYMX dated on 2013-07-11: Nymox Reports Positive Safety Monitoring Committee Results for Pivotal NX02-0017 Phase 3 Trial

Financial news for NYMX dated on 2013-04-02: Press Release Issued Under the Early Warning System/Sale of Shares of Nymox Pharmaceutical Corporation

Financial news for NYMX dated on 2013-02-19: UPDATE: Nymox Announces Positive Immunogenicity Results for NX-1207 BPH Program

Financial news for NYMX dated on 2013-02-19: Nymox Announces Positive Immunogenicity Results for NX-1207 BPH Program

Financial news for NYMX dated on 2012-08-14: Nymox Pharmaceutical Reports Q2 EPS \$-0.05 vs \$-0.06 Est

Financial news for NYMX dated on 2012-07-31: Nymox Reports Positive Results From Combined Statistical Analysis of Long Term Follow-Up Studies of BPH Drug

Financial news for NYMX dated on 2012-07-11: Nymox Announces Completion of Enrollment for Phase 3 BPH Re-Injection Study

Financial news for NYMX dated on 2012-07-09: Nymox Announces Positive Safety Monitoring Committee Results for Phase 3 BPH NX02-0020 Repeat Injection U.S. Study

Financial news for NYMX dated on 2012-06-12: Nymox Announces First Patient Enrollment for Phase 2 Prostate Cancer Clinical Trial

Financial news for NYMX dated on 2012-04-26: Nymox Announces Positive Safety Monitoring Committee Results for Phase 3 NX-1207 Trials for BPH

Financial news for NYMX dated on 2012-03-26: Nymox Announces New Positive Long-Term Follow-Up Study Results for Subjects Treated With NX-1207 for BPH

Financial news for NYMX dated on 2012-02-21: Recordati and Nymox Announce the Start of European Phase III Clinical Trial for NX-1207

Financial news for NYMX dated on 2012-02-15: Nymox Announces Current Safety Monitoring Committee Results and Update for Phase 3 NX-1207 Trials

Financial news for NYMX dated on 2011-10-20: Singular Research: 6th Annual Best of The Uncovereds Conference Preview

Financial news for NYMX dated on 2011-10-19: Nymox Pharmaceutical Announces New Positive Data on NX-1207 Presented at Symposium at American Urological Association Meeting October 19

Financial news for NYMX dated on 2011-09-26: New Peer-Reviewed Publication in Therapeutic Advances in Chronic Disease Features Nymox NX-1207 Drug for BPH

Financial news for NYMX dated on 2011-08-17: August 16 Safety Monitoring Committee Meeting for Nymox Pivotal Phase 3 NX-1207 Trials Indicates Favorable Safety Profile

Financial news for NYMX dated on 2011-08-16: Clinical Investigators to Present Data on Nymox BPH Drug at American Urological Association Meeting October 19

Financial news for NYMX dated on 2011-06-06: UPDATE: E. Coli Sympathy Stocks Include PURE Bioscience, Strategic Diagnostics, Nymox Pharma, Life Technologies, and Food Technology Service

Financial news for NYMX dated on 2011-05-17: Nymox Pharmaceutical Announces New Positive Data on NX-1207 Presented at Symposium at American Urological Association Annual Meeting

Financial news for NYMX dated on 2011-05-04: Safety Monitoring Committee Meeting Positive for Nymox Pivotal Phase 3 NX-1207 Trials

Financial news for NYMX dated on 2011-03-16: Nymox Announces Positive New Results in 7 Year Study of NX-1207 for Benign Prostatic Hyperplasia

Financial news for NYMX dated on 2010-12-31: Nymox Pharmaceutical Climbs 6.9% (NYMX)

Financial news for NYMX dated on 2010-12-23: Nymox Pharmaceutical Climbs 13.7% (NYMX)

Financial news for NYMX dated on 2010-12-17: Morning Market Movers (ITMN, BASI, NYMX, MI)

Financial news for NYMX dated on 2010-12-17: Nymox Up Huge After Recordati News (NYMX)

Financial news for NYMX dated on 2010-11-12: Nymox Reports Third Quarter 2010 Financial Results

Financial news for NYMX dated on 2010-08-05: Under \$5 Stocks at Risk of Defaulting

Financial news for NYMX dated on 2009-08-26: Nymox Pharmaceutical Corporation (NYMX) Announces Lead Drug in Development Shows Positive Results